首页> 美国卫生研究院文献>Cancers >Biomarkers for Precision Urothelial Carcinoma Diagnosis: Current Approaches and the Application of Single-Cell Technologies
【2h】

Biomarkers for Precision Urothelial Carcinoma Diagnosis: Current Approaches and the Application of Single-Cell Technologies

机译:精密尿路上皮癌诊断的生物标志物:目前的方法和单细胞技术的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Urothelial carcinoma (UC) is the most frequently diagnosed cancer of the urinary tract and is ranked the sixth most diagnosed cancer in men worldwide. About 70–75% of newly diagnosed UCs are non-invasive or low grade. Different tests such as urine cytology and cystoscopy are used to detect UC. If abnormal tissue is found during cystoscopy, then a biopsy will be performed. Cytology has low sensitivity for low-grade cancer while cystoscopy is invasive and costly. Detecting UC early improves the chances of treatment success. Therefore, many researchers have painstakingly identified urine biological markers for non-invasive UC diagnosis. In this review, we summarize some of the latest and most promising biological markers (including FDA-approved and investigational markers). We also discuss some new technologies that can aid research efforts in biological marker discovery for early UC detection.
机译:尿检癌(UC)是泌尿道最常见的疾病癌症,并在全世界的男性中排名第六次诊断。约70-75%的新诊断的UCS是非侵入性的或低级的。使用不同的测试,例如尿液细胞学和膀胱镜检查来检测UC。如果在膀胱镜检查期间发现异常组织,则将进行活组织检查。细胞学对低级癌症的敏感性低,同时膀胱镜检查是侵入性的且昂贵的。检测UC早期改善了治疗成功的机会。因此,许多研究人员对非侵入性的UC诊断具有良好鉴定的尿液生物学标志物。在本综述中,我们总结了一些最新和最有前途的生物标记(包括FDA批准和调查标志物)。我们还讨论了一些可以帮助研究努力在早期UC检测中获得生物标志发现的研究努力的新技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号